AMP Capital Investors Ltd raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,465 shares of the biotechnology company’s stock after acquiring an additional 4,931 shares during the quarter. AMP Capital Investors Ltd owned about 0.14% of United Therapeutics worth $7,894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of UTHR. First Trust Advisors LP raised its holdings in United Therapeutics by 53.8% during the 3rd quarter. First Trust Advisors LP now owns 1,053,569 shares of the biotechnology company’s stock valued at $134,730,000 after acquiring an additional 368,613 shares during the period. BlackRock Inc. raised its holdings in United Therapeutics by 2.3% during the 2nd quarter. BlackRock Inc. now owns 5,028,058 shares of the biotechnology company’s stock valued at $568,925,000 after acquiring an additional 115,073 shares during the period. Prudential Financial Inc. raised its holdings in United Therapeutics by 28.6% during the 3rd quarter. Prudential Financial Inc. now owns 465,230 shares of the biotechnology company’s stock valued at $59,493,000 after acquiring an additional 103,474 shares during the period. Greylin Investment Mangement Inc. raised its holdings in United Therapeutics by 206.7% during the 2nd quarter. Greylin Investment Mangement Inc. now owns 118,703 shares of the biotechnology company’s stock valued at $13,431,000 after acquiring an additional 80,006 shares during the period. Finally, Andra AP fonden bought a new stake in United Therapeutics during the 2nd quarter valued at $8,679,000. 97.24% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on UTHR shares. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a report on Thursday, August 16th. BidaskClub raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 18th. Standpoint Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 12th. Wedbush set a $253.00 target price on shares of United Therapeutics and gave the company a “buy” rating in a report on Thursday, September 27th. Finally, Oppenheimer set a $160.00 target price on shares of United Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 20th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $134.00.

UTHR opened at $112.77 on Friday. The firm has a market cap of $4.94 billion, a PE ratio of 10.36, a PEG ratio of 26.44 and a beta of 1.24. The company has a quick ratio of 4.05, a current ratio of 4.32 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a one year low of $100.57 and a one year high of $152.55.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 EPS for the quarter, missing analysts’ consensus estimates of $3.23 by ($0.81). The firm had revenue of $412.70 million for the quarter, compared to analysts’ expectations of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $4.69 earnings per share. Sell-side analysts forecast that United Therapeutics Co. will post 14.28 EPS for the current fiscal year.

In other news, Director Christopher Causey sold 810 shares of the business’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $119.00, for a total transaction of $96,390.00. Following the completion of the transaction, the director now directly owns 1,555 shares in the company, valued at approximately $185,045. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.20% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/amp-capital-investors-ltd-has-7-89-million-holdings-in-united-therapeutics-co-uthr/2666500.html.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Article: What impact do institutional investors have on markets?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.